LADENBURG THALM/SH SH Cuts electroCore (NASDAQ:ECOR) Price Target to $26.00

electroCore (NASDAQ:ECOR) had its target price trimmed by LADENBURG THALM/SH SH from $28.00 to $26.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of electroCore in a report on Thursday.

electroCore Price Performance

NASDAQ:ECOR opened at $8.56 on Thursday. electroCore has a one year low of $5.32 and a one year high of $19.49. The firm’s fifty day moving average price is $15.84 and its two-hundred day moving average price is $12.31. The company has a market cap of $56.98 million, a P/E ratio of -4.68 and a beta of 0.24.

Institutional Trading of electroCore

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its position in shares of electroCore by 31,250.0% during the 4th quarter. JPMorgan Chase & Co. now owns 3,762 shares of the company’s stock worth $61,000 after buying an additional 3,750 shares during the period. DnB Asset Management AS acquired a new stake in shares of electroCore during the 4th quarter worth approximately $180,000. HighTower Advisors LLC acquired a new stake in shares of electroCore during the 3rd quarter worth approximately $255,000. NewEdge Advisors LLC acquired a new stake in shares of electroCore during the 4th quarter worth approximately $274,000. Finally, Jane Street Group LLC acquired a new stake in shares of electroCore during the 4th quarter worth approximately $278,000. Institutional investors and hedge funds own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.